Gregory Bluemling, PhD

Publications

1. Welch, S. R.; Spengler, J. R.; Westover, J. B.; Bailey, K. W.; Davies, K. A.; Aida-Ficken, V.; Bluemling, G. R.; Boardman, K. M.; Wasson, S. R.; Mao, S.; Kuiper, D. L.; Hager, M. W.; Saindane, M. T.; Andrews, M. K.; Krueger, R. E.; Sticher, Z. M.; Jung, K. H.; Chatterjee, P.; Shrivastava-Ranjan, P.; Lo, M. K.; Coleman-McCray, J. D.; Sorvillo, T. E.; Genzer, S. C.; Scholte, F. E. M.; Kelly, J. A.; Jenks, M. H.; McMullan, L. K.; Albarino, C. G.; Montgomery, J. M.; Painter, G. R.; Natchus, M. G.; Kolykhalov, A. A.; Gowen, B. B.; Spiropoulou, C. F.; Flint, M. (2024). Delayed low-dose oral administration of 4’-fluorouridine inhibits pathogenic arenaviruses in animal models of lethal disease. Sci. Transl. Med., 16(774), 1-17.

2. Westover, J. B.; Jung, K. H.; Alkan, C.; Boardman, K. M.; Van Wettere, A. J.; Martens, C.; Rojas, I.; Hicks, P.; Thomas, A. J.; Saindane, M. T.; Bluemling, G. R.; Mao, S.; Kolykhalov, A. A.; Natchus, M. G.; Bates, P.; Painter, G. R.; Ikegami, T.; Gowen, B. B. (2024). Modeling Heartland virus disease in mice and therapeutic intervention with 4’-fluorouridine. J Virol., 98(4), e00132-24

3. Bluemling, G. R.; Mao, S.; Natchus, M. G.; Painter, W.; Mulangu, S.; Lockwood, M.; De La Rosa, A.; Brasel, T.; Comer, J. E.; Freiberg, A. N.; Kolykhalov, A. A.; Painter, G. R. (2023). The prophylactic and therapeutic efficacy of the broadly active ribonucleoside N4-Hydroxycytidine (EIDD-1931) in a mouse model of lethal Ebola virus infection. Antiviral Res., 209, 105453

4. Sourimant, J., Lieber, C. M., Aggarwal, M., Cox, R. M., Wolf, J. D., Yoon, J.-J., Toots, M., Ye, C., Sticher, Z., Kolykhalov, A. A., Martinez-Sobrido, L., Bluemling, G. R., Natchus, M. G., Painter, G. R., & Plemper, R. K. (2022). 4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. Science (Washington, DC, U. S.), 375(6577), 161-167. doi:10.1126/science.abj5508

5. Wahl, A., Gralinski, L. E., Johnson, C. E., Yao, W., Kovarova, M., Dinnon, K. H., III, Liu, H., Madden, V. J., Krzystek, H. M., De, C., White, K. K., Gully, K., Schafer, A., Zaman, T., Leist, S. R., Grant, P. O., Bluemling, G. R., Kolykhalov, A. A., Natchus, M. G., Askin, F. B., Painter, G., Browne, E. P., Jones, C. D., Pickles, R. J., Baric, R. S., & Garcia, J. V. (2021). SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature (London, U. K.), 591(7850), 451-457. doi:10.1038/s41586-021-03312-w

6. Sourimant, J., Lieber, C. M., Aggarwal, M., Cox, R. M., Wolf, J. D., Yoon, J.-J., Toots, M., Ye, C., Sticher, Z., Kolykhalov, A. A., Martinez-Sobrido, L., Bluemling, G. R., Natchus, M. G., Painter, G. R., & Plemper, R. K. (2021). 4'-Fluorouridine is a broad-spectrum orally efficacious antiviral blocking respiratory syncytial virus and SARS-CoV-2 replication. bioRxiv, 1-17. doi:10.1101/2021.05.19.444875

7. Sticher, Z. M., Lu, G., Mitchell, D. G., Marlow, J., Moellering, L., Bluemling, G. R., Guthrie, D. B., Natchus, M. G., Painter, G. R., & Kolykhalov, A. A. (2020). Analysis of the potential for N4-hydroxycytidine to inhibit mitochondrial replication and function. Antimicrob. Agents Chemother., 64(2), e01719. doi:10.1128/aac.01719-19

8. Squires, K. E., Mayers, D. L., Bluemling, G. R., Kolykhalov, A. A., Guthrie, D. B., Reddy, P., Mitchell, D. G., Saindane, M. T., Sticher, Z. M., Edpuganti, V., & De La Rosa, A. (2020). ATI-2173, a novel liver-targeted non-chain-terminating nucleotide for hepatitis B virus cure regimens. Antimicrob. Agents Chemother., 64(9), e00836. doi:10.1128/aac.00836-20

9. Sheahan, T. P., Sims, A. C., Zhou, S., Graham, R. L., Pruijssers, A. J., Agostini, M. L., Leist, S. R., Schafer, A., Dinnon, K. H., III, Stevens, L. J., Chappell, J. D., Lu, X., Hughes, T. M., George, A. S., Hill, C. S., Montgomery, S. A., Brown, A. J., Bluemling, G. R., Natchus, M. G., Saindane, M., Kolykhalov, A. A., Painter, G., Harcourt, J., Tamin, A., Thornburg, N. J., Swanstrom, R., Denison, M. R., & Baric, R. S. (2020). An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med., 12(541), eabb5883. doi:10.1126/scitranslmed.abb5883

10. Sheahan, T. P., Sims, A. C., Zhou, S., Graham, R. L., Hill, C. S., Leist, S. R., Schafer, A., Dinnon, K. H., III, Montgomery, S. A., Agostini, M. L., Pruijssers, A. J., Chapell, J. D., Brown, A. J., Bluemling, G. R.,Natchus, M. G., Saindane, M., Kolykhalov, A. A., Painter, G., Harcourt, J., Tamin, A., Thornburg, N. J., Swanstrom, R., Denison, M. R., & Baric, R. S. (2020). An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus. bioRxiv, 1-34. doi:10.1101/2020.03.19.997890

11. Toots, M., Yoon, J.-J., Cox, R. M., Hart, M., Sticher, Z. M., Makhsous, N., Plesker, R., Barrena, A. H., Reddy, P. G., Mitchell, D. G., Shean, R. C., Bluemling, G. R., Kolykhalov, A. A., Greninger, A. L., Natchus, M. G., Painter, G. R., & Plemper, R. K. (2019). Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci. Transl. Med., 11(515), eaax5866. doi:10.1126/scitranslmed.aax5866

12. Painter, G. R., Bowen, R. A., Bluemling, G. R., DeBergh, J., Edpuganti, V., Gruddanti, P. R., Guthrie, D. B., Hager, M., Kuiper, D. L., Lockwood, M. A., Mitchell, D. G., Natchus, M. G., Sticher, Z. M., & Kolykhalov, A. A. (2019). The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal Venezuelan equine encephalitis virus infection. Antiviral Res., 171, 104597. doi:10.1016/j.antiviral.2019.104597

13. Agostini, M. L., Pruijssers, A. J., Chappell, J. D., Gribble, J., Lu, X., Andres, E. L., Bluemling, G. R.,Lockwood, M. A., Sheahan, T. P., Sims, A. C., Natchus, M. G., Saindane, M., Kolykhalov, A. A., Painter, G. R., Baric, R. S., & Denison, M. R. (2019). Small-molecule antiviral β-D-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J. Virol., 93(24), e01348. doi:10.1128/jvi.01348-19

14. Lu, G., Bluemling, G. R., Mao, S., Hager, M., Gurale, B. P., Collop, P., Kuiper, D., Sana, K., Painter, G. R., De La Rosa, A., & Kolykhalov, A. A. (2018). Simple in vitro assay to evaluate the incorporation efficiency of ribonucleotide analog 5'-triphosphates into RNA by human mitochondrial DNA-dependent RNA polymerase. Antimicrob. Agents Chemother., 62(2), 1-18. doi:10.1128/aac.01830-17

15. Lu, G., Bluemling, G. R., Collop, P., Hager, M., Kuiper, D., Gurale, B. P., Painter, G. R., De La Rosa, A., & Kolykhalov, A. A. (2017). Analysis of ribonucleotide 5′-triphosphate analogs as potential inhibitors of zika virus RNA-dependent RNA polymerase by using nonradioactive polymerase assays. Antimicrob. Agents Chemother., 61(3), e01967. doi:10.1128/aac.01967-16

16. Kuhlmann, F. M., Robinson, J. I., Bluemling, G. R., Ronet, C., Fasel, N., & Beverley, S. M. (2017). Antiviral screening identifies adenosine analogs targeting the endogenous dsRNA Leishmania RNA virus 1 (LRV1) pathogenicity factor. Proc. Natl. Acad. Sci. U. S. A., 114(5), E811. doi:10.1073/pnas.1619114114.

17. Welch, S. R., Guerrero, L. W., Chakrabarti, A. K., McMullan, L. K., Flint, M., Bluemling, G. R., Painter, G. R., Nichol, S. T., Spiropoulou, C. F., & Albarino, C. G. (2016). Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems. Antiviral Res., 136, 9-18. doi:10.1016/j.antiviral.2016.10.007

Current PCT Publications

1. Painter, G. R., Perryman, D., & Bluemling, G. R. (2022). 4'-Halogen containing nucleotide and nucleoside therapeutic compositions and uses. WO2022174194.

2. Painter, G. R., Perryman, D., & Bluemling, G. R. (2022). 4'-Halogen containing nucleotide and nucleoside therapeutic compositions and uses. WO2022174179.

3. Painter, G. R., Perryman, D., & Bluemling, G. R. (2021). Preparation of 4'-halogen containing nucleotide and nucleoside therapeutics and uses related thereto. WO2021137913.

4. Painter, G. R., Bluemling, G. R., Natchus, M. C., Mao, S., Marengo, J., Hager, M. W., & Perryman, D. (2021). N4-hydroxycytidine and derivatives and anti-viral uses related thereto. WO2021159044.

5. Painter, G. R., Perryman, D., & Bluemling, G. R. (2019). Preparation of 4'-halogen containing nucleotide and nucleoside therapeutics and uses related thereto. WO2019173602.

6. Painter, G. R., Bluemling, G. R., Natchus, M. G., & Guthrie, D. (2019). Preparation of N4-hydroxycytidine and derivatives and antiviral uses related thereto. WO2019113462.

7. Painter, G. R., Guthrie, D. B., Bluemling, G. R., & Natchus, M. R. (2017). Preparation of N4-hydroxycytidine and derivatives and antiviral uses related thereto. WO2017156380.

8. Painter, G., Bluemling, G. R., De La Rosa, A., Liotta, D. C., & Kuiper, D. (2017). Preparation of nucleotide and nucleoside therapeutic compositions and uses related thereto as antiviral agents. WO2017155923.

9. Painter, G., Bluemling, G. R., De La Rosa, A., & Liotta, D. C. (2017). Preparation of nucleotide and nucleoside therapeutic compositions and uses related thereto as antiviral agents. WO2017106710.

10. De la Rosa, A., Painter, G., & Bluemling, G. R. (2017). Preparation of pyrimidine nucleoside 5'-phosphoramidates for the treatment of hepatitis B virus. WO2017223421.

11. Bluemling, G.R., De la Rosa, A., Painter, G., Kuiper, D., & Kolykhalov, A. (2017). Preparation of alkyne containing nucleosides and nucleotides as antiviral agents. WO2017189978.

12. Painter, G. R., Guthrie, D. B., Bluemling, G. R., & Natchus, M. G. (2016). Preparation of N4-hydroxycytidine and derivatives and antiviral uses related thereto. WO2016106050.

13. Liotta, D. C., Painter, G. R., Bluemling, G. R., & De la Rosa, A. (2016). Preparation of amino acid-containing nucleotide and nucleoside triphosphates as antiviral agents. WO2016145142.

14. De la Rosa, A., Painter, G., & Bluemling, G. R. (2016). Phosphoramidates for the treatment of hepatitis B virus. WO2016099982.

15. Liotta, D. C., Painter, G. R., Bluemling, G. R., & De La Rosa, A. (2015). Preparation of amino acid-containing nucleotide and nucleoside triphosphates as antiviral agents. WO2015038596.

16. Liotta, D. C., Painter, G. R., & Bluemling, G. R. (2014). Preparation of nucleotides and nucleosides as antitumor and antiviral agents. WO2014124430.